Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Palella, F. J., Jr.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4⁺ Cell Strata

Frank J. Palella, Jr., MD; Maria Deloria-Knoll, PhD; Joan S. Chmiel, PhD; Anne C. Moorman, BSN, MPH; Kathleen C. Wood, BSN; Alan E. Greenberg, MD, MPH; Scott D. Holmberg, MD, MPH, the HIV Outpatient Study (HOPS) Investigators*

15 April 2003 | Volume 138 Issue 8 | Pages 620-626

Background: Optimal timing of antiretroviral therapy (ART) initiation for HIV-infected persons remains unclear.

Objective: To assess survival benefit of initiating ART at different CD4⁺ cell counts.

Design: Prospective observational study.

Setting: U.S. clinics in the HIV Outpatient Study (HOPS).

Patients: HIV-infected patients with CD4⁺ cell counts, plasma HIV RNA viral load, and ART use recorded from January 1994 through March 2002.

Measurements: Before initiation of ART, patients were grouped by their CD4⁺ cell counts into three subgroups: 0.201 to 0.350 x 10⁹ cells/L (n = 399), 0.351 to 0.500 x 10⁹ cells/L (n = 327), and 0.501 to 0.750 x 10⁹ cells/L (n = 122). We compared mortality rates for each CD4⁺ subgroup among patients who initiated ART and patients who delayed ART until reaching a lower CD4⁺ subgroup.

Results: Mortality rates for 340 patients who initiated ART and 59 who delayed ART in the CD4⁺ subgroup of 0.201 to 0.350 x 10⁹ cells/L were 15.4 and 56.4 deaths per 1000 person-years, respectively (rate ratio, 0.27 [95% CI, 0.14 to 0.55]; P < 0.001). For the CD4⁺ subgroup of 0.351 to 0.500 x 10⁹ cells/L, mortality rates for 240 patients who initiated ART and 887 who delayed ART were 10.0 and 16.6 deaths per 1000 person-years, respectively (rate ratio, 0.61 [CI, 0.22 to 1.67]; P = 0.17). For the CD4⁺ subgroup of 0.501 to 0.750 x 10⁹ cells/L, mortality rates in 55 patients who initiated ART and 67 who delayed ART were 7.5 and 3.1 deaths per 1000 person-years, respectively (rate ratio, 1.20 [CI, 0.17 to 8.53]; P > 0.2). Patients in the 0.201 to 0.350 x 10⁹ cells/L and 0.351 to 0.500 x 10⁹ cells/L CD4⁺ subgroups who initiated ART were more likely than those who delayed ART to achieve an undetectable HIV viral load (P = 0.03 and 0.04, respectively).

Conclusions: Among HIV-infected persons with CD4⁺ cell counts of 0.201 to 0.350 x 10⁹ cells/L, initiating ART is associated with reduced mortality compared with delaying such therapy. Survival benefits of earlier ART initiation (at CD4⁺ cell counts of 0.351 to 0.500 x 10⁹ cells/L) are possible.

*For the HOPS Investigators, see Appendix.

Editors' Notes Context When to start antiretroviral therapy (ART) for HIV infection is controversial. Starting too early exposes patients to side effects and uncertain benefits. Starting too late deprives patients of benefits. Contribution In this cohort study, HIV-infected patients with baseline CD4+ cell counts between 0.201 and 0.350 x 109 cells/L who began ART immediately had lower mortality rates than those who started therapy after their CD4+ cell count decreased to less than 0.201 x 109 cells/L. Optimal timing of therapy is unclear when the CD4+ cell count is greater than 0.350 x 109 cells/L. Cautions A randomized, controlled trial is the best way to identify the optimal timing of ART. –The Editors

 

Author and Article Information

From Northwestern University, Chicago, Illinois; National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and APACHE Medical Systems, Cerner Corporation, Vienna, Virginia.

Acknowledgment: The authors thank John P. Phair, MD, Professor Emeritus of Medicine, The Feinberg School of Medicine, Northwestern University, for his ongoing support, insight, and sage advice.

Grant Support: By the Centers for Disease Control and Prevention (contract 200-2001-00133), Atlanta, Georgia.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Frank J. Palella Jr., MD, Division of Infectious Diseases, The Feinberg School of Medicine, Northwestern University, 676 North Saint Clair, Suite 200, Chicago, IL 60611; e-mail, f-palella{at}northwestern.edu.

Current Author Addresses: Dr. Palella: Division of Infectious Diseases, The Feinberg School of Medicine, Northwestern University, 676 North Saint Clair, Suite 200, Chicago, IL 60611.

Drs. Deloria-Knoll and Chmiel: Department of Preventive Medicine, The Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611.

Ms. Moorman, Dr. Greenberg, and Dr. Holmberg: Centers for Disease Control and Prevention, Mailstop E-45, 1600 Clifton Road, Atlanta, GA 30333.

Ms. Wood: Cerner Corporation, 2800 Rockcreek Parkway, Kansas City, MO 64117.

Author Contributions: Conception and design: F.J. Palella, M. Deloria-Knoll, J.S. Chmiel, A.C. Moorman, S.D. Holmberg.

Analysis and interpretation of the data: F.J. Palella, M. Deloria-Knoll, J.S. Chmiel, A.C. Moorman, A.E. Greenberg, S.D. Holmberg.

Drafting of the article: F.J. Palella.

Critical revision of the article for important intellectual content: F.J. Palella, M. Deloria-Knoll, J.S. Chmiel, A.C. Moorman, A.E. Greenberg, S.D. Holmberg.

Final approval of the article: F.J. Palella, M. Deloria-Knoll, J.S. Chmiel, A.C. Moorman, K.C. Wood, A.E. Greenberg, S.D. Holmberg.

Provision of study materials or patients: F.J. Palella.

Statistical expertise: M. Deloria-Knoll, J.S. Chmiel.

Obtaining of funding: K.C. Wood.

Administrative, technical, or logistic support: F.J. Palella, A.C. Moorman, K.C. Wood, S.D. Holmberg.

Collection and assembly of data: F.J. Palella, A.C. Moorman, K.C. Wood, S.D. Holmberg.

Related articles in Annals:

Editorials
When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data
H. Clifford Lane AND James D. Neaton

Annals 2003 138: 680-681. [Full Text]  

Summaries for Patients
Immediate versus Delayed Treatment for HIV Infection

Annals 2003 138: I-28. [Full Text]  

Letters
HIV Survival Benefit Associated with Earlier Antiviral Therapy
Amanda Mocroft, Andrew N. Phillips, AND Jens D. Lundgren

Annals 2004 140: 578-579. [Full Text]  

Letters
HIV Survival Benefit Associated with Earlier Antiviral Therapy
Frank J. Palella, Jr., Joan S. Chmiel, AND Scott D. Holmberg

Annals 2004 140: 579. [Full Text]  

This article has been cited by other articles:

				R. S. Braithwaite, M. S. Roberts, C. C. H. Chang, M. B. Goetz, C. L. Gibert, M. C. Rodriguez-Barradas, S. Shechter, A. Schaefer, K. Nucifora, R. Koppenhaver, et al. Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model Ann Intern Med, February 5, 2008; 148(3): 178 - 185. [Abstract] [Full Text] [PDF]

				S. M. Shechter, M. D. Bailey, A. J. Schaefer, and M. S. Roberts The Optimal Time to Initiate HIV Therapy Under Ordered Health States Operations Research, January 1, 2008; 56(1): 20 - 33. [Abstract] [PDF]

				Missed Opportunities for Earlier Diagnosis of HIV Infection--South Carolina, 1997-2005 JAMA, January 10, 2007; 297(2): 149 - 150. [Full Text] [PDF]

				S. J. Goldie, Y. Yazdanpanah, E. Losina, M. C. Weinstein, X. Anglaret, R. P. Walensky, H. E. Hsu, A. Kimmel, C. Holmes, J. E. Kaplan, et al. Cost-Effectiveness of HIV Treatment in Resource-Poor Settings -- The Case of Cote d'Ivoire N. Engl. J. Med., September 14, 2006; 355(11): 1141 - 1153. [Abstract] [Full Text] [PDF]

				E. J. Bini, J. Park, and F. Francois Use of Flexible Sigmoidoscopy to Screen for Colorectal Cancer in HIV-Infected Patients 50 Years of Age and Older. Arch Intern Med, August 14, 2006; 166(15): 1626 - 1631. [Abstract] [Full Text] [PDF]

				R. MacGowan, G. Eldridge, J. M. Sosman, R. Khan, T. Flanigan, B. Zack, A. Margolis, J. Askew, C. Fitzgerald, and Project START Study Group HIV Counseling and Testing of Young Men in Prison Journal of Correctional Health Care, July 1, 2006; 12(3): 203 - 213. [Abstract] [PDF]

				S. G Deeks Antiretroviral treatment of HIV infected adults. BMJ, June 24, 2006; 332(7556): 1489 - 1489. [Full Text] [PDF]

				P. Y. Hsue and D. D. Waters What a Cardiologist Needs to Know About Patients With Human Immunodeficiency Virus Infection Circulation, December 20, 2005; 112(25): 3947 - 3957. [Abstract] [Full Text] [PDF]

				S. M. Hammer Clinical practice. Management of newly diagnosed HIV infection. N. Engl. J. Med., October 20, 2005; 353(16): 1702 - 1710. [Full Text] [PDF]

				H. Chu, S. J. Gange, T. E. Yamashita, D. R. Hoover, J. S. Chmiel, J. B. Margolick, and L. P. Jacobson Individual Variation in CD4 Cell Count Trajectory among Human Immunodeficiency Virus-infected Men and Women on Long-term Highly Active Antiretroviral Therapy: An Application using a Bayesian Random Change-Point Model Am. J. Epidemiol., October 15, 2005; 162(8): 787 - 797. [Abstract] [Full Text] [PDF]

				L. M. Almond, P. G. Hoggard, D. Edirisinghe, S. H. Khoo, and D. J. Back Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals J. Antimicrob. Chemother., October 1, 2005; 56(4): 738 - 744. [Abstract] [Full Text] [PDF]

				S. Lohrengel, F. Hermann, I. Hagmann, H. Oberwinkler, L. Scrivano, C. Hoffmann, D. von Laer, and M. T. Dittmar Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides J. Virol., August 15, 2005; 79(16): 10237 - 10246. [Abstract] [Full Text] [PDF]

				R. Chou, L. H. Huffman, R. Fu, A. K. Smits, and P. T. Korthuis Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 5, 2005; 143(1): 55 - 73. [Abstract] [Full Text] [PDF]

				A. Winston and M. Boffito The management of HIV-1 protease inhibitor pharmacokinetic interactions J. Antimicrob. Chemother., July 1, 2005; 56(1): 1 - 5. [Abstract] [Full Text] [PDF]

				A. K Sullivan, H. Curtis, C. A Sabin, and M. A Johnson Newly diagnosed HIV infections: review in UK and Ireland BMJ, June 4, 2005; 330(7503): 1301 - 1302. [Full Text] [PDF]

				D. Vlahov, N. Galai, M. Safaeian, S. Galea, G. D. Kirk, G. M. Lucas, and T. R. Sterling Effectiveness of Highly Active Antiretroviral Therapy among Injection Drug Users with Late-Stage Human Immunodeficiency Virus Infection Am. J. Epidemiol., June 1, 2005; 161(11): 999 - 1012. [Abstract] [Full Text] [PDF]

				K. Manavi and P. D Welsby HIV testing BMJ, March 5, 2005; 330(7490): 492 - 493. [Full Text] [PDF]

				G. D. Sanders, A. M. Bayoumi, V. Sundaram, S. P. Bilir, C. P. Neukermans, C. E. Rydzak, L. R. Douglass, L. C. Lazzeroni, M. Holodniy, and D. K. Owens Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy N. Engl. J. Med., February 10, 2005; 352(6): 570 - 585. [Abstract] [Full Text] [PDF]

				M. Elrefaei, M. D. McElroy, C. P. Preas, R. Hoh, S. Deeks, J. Martin, and H. Cao Central Memory CD4+ T Cell Responses in Chronic HIV Infection Are Not Restored by Antiretroviral Therapy J. Immunol., August 1, 2004; 173(3): 2184 - 2189. [Abstract] [Full Text] [PDF]

				P. G. Yeni, S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. J. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, et al. Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel JAMA, July 14, 2004; 292(2): 251 - 265. [Abstract] [Full Text] [PDF]

				A. Mocroft and J. D. Lundgren Starting highly active antiretroviral therapy: why, when and response to HAART J. Antimicrob. Chemother., July 1, 2004; 54(1): 10 - 13. [Abstract] [Full Text] [PDF]

				J. K. Rockstroh and S. Mauss Clinical perspective of fusion inhibitors for treatment of HIV J. Antimicrob. Chemother., May 1, 2004; 53(5): 700 - 702. [Abstract] [Full Text] [PDF]

				A. Mocroft, A. N. Phillips, and J. D. Lundgren HIV Survival Benefit Associated with Earlier Antiviral Therapy Ann Intern Med, April 6, 2004; 140(7): 578 - 579. [Full Text] [PDF]

				J. M. Jacobson, R. J. Israel, I. Lowy, N. A. Ostrow, L. S. Vassilatos, M. Barish, D. N. H. Tran, B. M. Sullivan, T. J. Ketas, T. J. O'Neill, et al. Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542 Antimicrob. Agents Chemother., February 1, 2004; 48(2): 423 - 429. [Abstract] [Full Text] [PDF]

				P. R. Skolnik HIV Therapy -- What Do We Know, and When Do We Know It? N. Engl. J. Med., December 11, 2003; 349(24): 2351 - 2352. [Full Text] [PDF]

				K. A. McGinnis, M. J. Fine, R. K. Sharma, M. Skanderson, J. H. Wagner, M. C. Rodriguez-Barradas, L. Rabeneck, and A. C. Justice Understanding Racial Disparities in HIV Using Data From the Veterans Aging Cohort 3-Site Study and VA Administrative Data Am J Public Health, October 1, 2003; 93(10): 1728 - 1733. [Abstract] [Full Text] [PDF]

				Late Versus Early Testing of HIV--16 Sites, United States, 2000-2003 JAMA, July 23, 2003; 290(4): 455 - 457. [Full Text] [PDF]

				When to Start Antiretrovirals: Another Look AIDS Clinical Care, June 1, 2003; 2003(601): 1 - 1. [Full Text]

				H. C. Lane and J. D. Neaton When To Start Therapy for HIV Infection: A Swinging Pendulum in Search of Data Ann Intern Med, April 15, 2003; 138(8): 680 - 681. [Full Text] [PDF]